Critical Contrast: BeOne Medicines (NASDAQ:ONC) vs. PainReform (NASDAQ:PRFX)

BeOne Medicines (NASDAQ:ONC) and PainReform (NASDAQ:PRFX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for BeOne Medicines and PainReform, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0	2	13	2	3.00
PainReform	1	0	0	0	1.00

BeOne Medicines presently has a consensus target price of $404.93, indicating a potential upside of 16.00%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than PainReform.

Institutional and Insider Ownership

48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 34.4% of PainReform shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares BeOne Medicines and PainReform’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
PainReform	N/A	N/A	N/A

Earnings and Valuation

This table compares BeOne Medicines and PainReform”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34 billion	7.17	$286.93 million	$5.68	61.46
PainReform	$20,000.00	35.58	-$5.02 million	($736.66)	-0.00

BeOne Medicines has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BeOne Medicines has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, PainReform has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Summary

BeOne Medicines beats PainReform on 12 of the 15 factors compared between the two stocks.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.